Astrazeneca’s new medication for type 2 diabetes

MANILA, Philippines - AstraZeneca recently launched its new once-daily oral medication to aid Filipino adult patients with type 2 diabetes manage their condition better through the removal of excess glucose and its associated calories in the urine. At the launch are  Dr. Emman Arca, senior medical affairs manager, AstraZeneca; Dr. Chinnie Tan-Pineda, medical and regulatory affairs director, AstraZeneca; Dr. Merlin Thomas, physician scientist at the Baker IDI Heart and Diabetes Institute; Dr. Araceli Panelo, chairman of the board, Institute for Studies on Diabetes Foundation Inc. (ISDFI); Dr. Roberto Mirasol, past president, Philippine Society of Endocrinology, Diabetes & Metabolism (PSEDM); Lotis Ramin, marketing director, AstraZeneca; Dr. Stephan Matthaei, director of the Diabetes, Metabolism and Endocrinology Center, Quakenbrück Hospital; Marq Marquez, senior brand manager, AstraZeneca; and Dr. Lyra Agustin, medical science liaison, AstraZeneca.